RGEN · US market

Repligen Corp

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$10.00bnFinancials dated 30 June 2026Price dated 1 October 2026

Core valuation

Trailing P/E240.79×

Latest-quarter run-rate P/E499.31×

Trailing P/S12.74×

Latest-quarter run-rate P/S12.25×

Calculation inputs

Trailing earnings: US$41.54m
Latest-quarter run-rate earnings: US$20.03m
Latest fiscal-year earnings: US$48.89m
Trailing revenue: US$785.10m
Latest-quarter run-rate revenue: US$816.51m
Latest fiscal-year revenue: US$738.26m

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

BCSSX · Brown Capital Management Small Company Fund Institutional Shares4.45% weight · Holdings dated 30 June 2026
CCSMX · Conestoga SMid Cap Fund Investors Class3.26% weight · Holdings dated 30 June 2026
WGROX · Wasatch Core Growth Fund3.08% weight · Holdings dated 30 June 2026
FBT · First Trust NYSE Arca Biotechnology Index Fund3.07% weight · Holdings dated 30 June 2026
CCALX · Conestoga Small Cap Institutional Class2.88% weight · Holdings dated 30 June 2026
WAUSX · Wasatch U.S. Select Fund Investor Class2.56% weight · Holdings dated 30 June 2026
DFSGX · DF Dent Small Cap Growth Fund Institutional Shares2.54% weight · Holdings dated 30 June 2026
THCRX · Thornburg Focus Growth Fund Class R32.52% weight · Holdings dated 30 June 2026
IBBQ · Invesco Nasdaq Biotechnology ETF2.50% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
PBE · Invesco Biotechnology & Genome ETF2.50% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 June 2026. Informational research, not investment advice.